@article{JTD577,
author = {Deborah Enting and James Spicer},
title = {EGFR inhibition and more: a new generation growing up},
journal = {Journal of Thoracic Disease},
volume = {4},
number = {6},
year = {2012},
keywords = {},
abstract = {The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) has led to a shift in treatment paradigm for some patients with advanced disease. Mutations in exons 18-21 in the tyrosine kinase domain are associated with improved clinical outcomes following treatment with tyrosine kinase inhibitors (TKIs). The first-generation EGFR TKIs erlotinib and gefitinib are most effective in the presence of EGFR mutations (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/577}
}